Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Efficacy/Safety of Midurethral Sling

NCT05255289 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2021-03-08
Last updated
2025-09-05

Condition(s) studied

Stress Urinary Incontinence

Investigational drug(s) / intervention(s)

Urodynamic investigations before and after a trans-obturator tape protocol.Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)Urodynamic investigations before and after a mini Arc protocol.Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.Urodynamic investigations before and after an Solyx sling protocol.

Urodynamic investigations before and after a trans-obturator tape protocol.: Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)

Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O): Urodynamic investigations (stated above.)

Urodynamic investigations before and after a mini Arc protocol.: Urodynamic investigations (stated above)

Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.: Urodynamic investigations (stated above)

Urodynamic investigations before and after an Solyx sling protocol.: Urodynamic investigations (stated above.)

Study summary

The trans-obturator tape (TOT), which exhibits a satisfactory cure rate and a relatively diminished invasiveness, has been increasingly accepted as a surgical treatment of stress urinary incontinence (SUI) patients. Nevertheless, in contrast to the well-recognized therapeutic benefit of the enhanced resistance to the bladder continence during urine storage, if the voiding function of the bladder adapts to the TOT-enhanced outlet resistance has not been adequately investigated. This study retrospectively assayed the voiding efficacy of each voiding cycle, to clarify if the thermodynamic efficacy of the bladder was modified in response to the TOT surgery.

Eligibility

Sex
FEMALE
Min age
30 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of stress urinary incontience * Have urodynamic investigations before and after operation. Exclusion Criteria: * Exclusion criteria will be a history of (1) cardiovascular, (2) neurological, or (3) other medical (such as diabetes or inflammation) problems as well as (4) patients who received a concomitant surgical procedure.

Primary outcome measure(s)

  • Pressure-volume study — within a voiding cycle (a cycle is about 30 to 60 minutes)
    urine leakage.

Trial sites (1)

FacilityCityRegionStatus
Department of Obstetrics and Gynecology New Taipei City Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05255289 on ClinicalTrials.gov ↗ ← All trials in Taiwan